# Improving 24-hour Blood Pressure in Obstructive Sleep Apnea

> **NCT04021550** · EARLY_PHASE1 · WITHDRAWN · sponsor: **University of British Columbia**

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DEVICE:** Continuous Positive Airway Pressure CPAP
- **DRUG:** Telmisartan 80mg
- **DIETARY_SUPPLEMENT:** Alpha-Lipoic Acid 600mg
- **OTHER:** Microcrystalline Cellulose

## Key facts

- **NCT ID:** NCT04021550
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Covid-19 Pandemic prevented this study from beginning
- **Last updated:** 2023-05-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04021550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04021550, "Improving 24-hour Blood Pressure in Obstructive Sleep Apnea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04021550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*